AI-powered regulatory submission automation for clinical development
Artos builds AI tools that compress the regulatory submission lifecycle in biopharma — turning weeks of manual work into days. The stack (FastAPI, React, GraphQL, AWS) reflects a modern SaaS architecture, but the real signal is the project list: they're balancing core platform development with GenAI applications and customer-specific deployment workflows, while simultaneously stress-testing outputs against real regulatory standards. Early-stage hiring (2–10 people, half engineering) paired with pain points around scaling and regulatory soundness suggests they're in the critical phase of proving AI reliability to a skeptical industry before rapid growth.
Artos automates regulatory document creation and management for clinical development and medical writing teams at life sciences companies. The core problem is acute: the biopharma industry spends billions annually and millions of person-hours on regulatory submissions to health agencies. Artos' platform accelerates this by using AI to generate submissions and manage documentation workflows. The company is headquartered in San Francisco and operates as a privately held startup with a team concentrated in the United States. Current focus areas include containerized platform deployment, GenAI feature development, enterprise SaaS UI, and non-clinical/CMC domain-specific documentation systems.
FastAPI and Django on the backend, React and TypeScript on the frontend, with AWS infrastructure, Docker containerization, and GraphQL/Protocol Buffers for data transport. CI/CD runs on CircleCI and AWS CodePipeline.
San Francisco, CA. The company is hiring only in the United States and is a privately held startup with 2–10 employees.
Other companies in the same industry, closest in size
Artos AI's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.